ATE463502T1 - Menschliche toll-homologe - Google Patents

Menschliche toll-homologe

Info

Publication number
ATE463502T1
ATE463502T1 AT07020354T AT07020354T ATE463502T1 AT E463502 T1 ATE463502 T1 AT E463502T1 AT 07020354 T AT07020354 T AT 07020354T AT 07020354 T AT07020354 T AT 07020354T AT E463502 T1 ATE463502 T1 AT E463502T1
Authority
AT
Austria
Prior art keywords
human toll
pro286
pro285
toll homologue
pro358
Prior art date
Application number
AT07020354T
Other languages
English (en)
Inventor
Audrey Goddard
Paul Godowski
Austin Gurney
Melanie Mark
Ruey-Bing Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27535565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE463502(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE463502T1 publication Critical patent/ATE463502T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
AT07020354T 1997-10-17 1998-10-07 Menschliche toll-homologe ATE463502T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6225097P 1997-10-17 1997-10-17
US6531197P 1997-11-13 1997-11-13
US8332298P 1998-04-28 1998-04-28
US9086398P 1998-06-26 1998-06-26
US10541398A 1998-06-26 1998-06-26

Publications (1)

Publication Number Publication Date
ATE463502T1 true ATE463502T1 (de) 2010-04-15

Family

ID=27535565

Family Applications (3)

Application Number Title Priority Date Filing Date
AT07020354T ATE463502T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe
AT05023238T ATE381574T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe
AT98953294T ATE314471T1 (de) 1997-10-17 1998-10-07 Menschliche toll homologen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT05023238T ATE381574T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe
AT98953294T ATE314471T1 (de) 1997-10-17 1998-10-07 Menschliche toll homologen

Country Status (11)

Country Link
EP (3) EP1025227B1 (de)
JP (3) JP4319348B2 (de)
AT (3) ATE463502T1 (de)
AU (1) AU1070399A (de)
CA (1) CA2305385C (de)
DE (3) DE69833014T2 (de)
DK (3) DK1650219T3 (de)
ES (2) ES2343210T3 (de)
IL (4) IL135345A0 (de)
PT (2) PT1887014E (de)
WO (1) WO1999020756A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696327B1 (en) 1997-10-17 2010-04-13 Genentech, Inc. Antibodies to human Toll homologues
AU2001264889B2 (en) * 1997-05-07 2006-06-29 Schering Corporation Human receptor proteins; related reagents and methods
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
ES2279572T3 (es) * 1997-05-07 2007-08-16 Schering Corporation Proteinas receptoras humanas de tipo toll, reactivos y metodos relacionados.
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
NZ522327A (en) * 2000-05-25 2004-09-24 Schering Corp Mammalian DNAX Toll-like receptor protein, DTLR 10, antibodies and medicaments made therefrom and use in treating immunological disorders
WO2002022809A2 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1293566A1 (de) * 2001-09-17 2003-03-19 Societe Des Produits Nestle S.A. Ein löslicher Toll-ähnlicher Rezeptor
KR20040099418A (ko) * 2002-04-08 2004-11-26 다케다 야쿠힌 고교 가부시키가이샤 중증 패혈증 예방 치료제
ATE500842T1 (de) 2002-05-04 2011-03-15 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
EP1590469A4 (de) 2002-11-12 2005-12-28 Becton Dickinson Co Sepsis- oder sirs-diagnose mittels biomarkerprofilen
AU2003295649A1 (en) * 2002-11-22 2004-06-18 Nuvelo,Inc. Methods of therapy and diagnosis
EP1631687A2 (de) * 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Verfahren und produkte zur identifizierung und beurteilung von tlr-liganden
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
JP2007532094A (ja) * 2003-05-16 2007-11-15 アコーダ セラピューティクス、インク． Ｃｎｓ治療用のプロテオグリカン分解変異体
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US8163506B2 (en) 2003-06-17 2012-04-24 Meiji Co., Ltd. Use of toll-like receptor-expressing cells
JP4562123B2 (ja) * 2003-06-17 2010-10-13 明治乳業株式会社 Ｔｏｌｌ様レセプター強制発現細胞の利用
EP1668035A2 (de) 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoklonale antikörper gegen hmgb1
ES2411504T3 (es) 2004-05-18 2013-07-05 Acorda Therapeutics, Inc. Métodos de purificación de condroitinasa y formulaciones estables de la misma
US8039588B2 (en) * 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
KR20080006617A (ko) 2005-04-15 2008-01-16 백톤 디킨슨 앤드 컴퍼니 패혈증의 진단
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
DK1945820T3 (da) * 2005-10-27 2013-11-11 Janssen Biotech Inc Toll-lignende receptor-3-modulatorer, fremgangsmåder og anvendelser
JP2009536022A (ja) * 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、それに関連する組成物および方法
JP5391069B2 (ja) 2006-10-10 2014-01-15 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を使用する組成物及び方法
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
EP2528598B1 (de) 2010-01-27 2016-01-13 Takeda Pharmaceutical Company Limited Verbindungen zur unterdrückung eines durch ein krebsmedikament herbeigeführten peripheren nervenleidens
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2279572T3 (es) * 1997-05-07 2007-08-16 Schering Corporation Proteinas receptoras humanas de tipo toll, reactivos y metodos relacionados.
EP1386931B1 (de) * 1998-03-25 2006-05-10 Genentech, Inc. Menschliches Neurotrimin-Homolog

Also Published As

Publication number Publication date
EP1650219A1 (de) 2006-04-26
JP5425244B2 (ja) 2014-02-26
AU1070399A (en) 1999-05-10
ATE381574T1 (de) 2008-01-15
ES2298905T3 (es) 2008-05-16
EP1887014B1 (de) 2010-04-07
JP2012105662A (ja) 2012-06-07
WO1999020756A2 (en) 1999-04-29
JP4319348B2 (ja) 2009-08-26
IL180967A (en) 2012-09-24
DK1650219T3 (da) 2008-05-05
IL180967A0 (en) 2007-07-04
PT1887014E (pt) 2010-07-05
JP2009131265A (ja) 2009-06-18
DK1887014T3 (da) 2010-08-02
DE69838888T2 (de) 2008-12-11
ES2343210T3 (es) 2010-07-26
CA2305385A1 (en) 1999-04-29
IL221367A (en) 2015-06-30
DE69838888D1 (de) 2008-01-31
DE69833014T2 (de) 2006-08-10
IL135345A (en) 2007-06-03
JP5027105B2 (ja) 2012-09-19
PT1650219E (pt) 2008-03-31
EP1025227B1 (de) 2005-12-28
CA2305385C (en) 2013-05-21
WO1999020756A3 (en) 1999-09-10
EP1025227A2 (de) 2000-08-09
IL135345A0 (en) 2001-05-20
DE69833014D1 (de) 2006-02-02
EP1887014A1 (de) 2008-02-13
ATE314471T1 (de) 2006-01-15
DE69841607D1 (de) 2010-05-20
DK1025227T3 (da) 2006-05-01
JP2002526028A (ja) 2002-08-20
EP1650219B1 (de) 2007-12-19

Similar Documents

Publication Publication Date Title
ATE381574T1 (de) Menschliche toll-homologe
HK1211618A1 (en) Nogo receptor binding protein nogo
IL131016A0 (en) Selection of proteins using rna-protein fusions
ATE329028T1 (de) Nl3 tie rezeptortyrosinekinase ligandhomologe
DE69813158T2 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
DE69839444D1 (de) Smad 6 und dessen anwendungen
PT868519E (pt) Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')
DE59712604D1 (de) Mittel zur identifizierung und therapie metastasierender tumore
WO2001021794A3 (en) Smad associating polypeptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1887014

Country of ref document: EP